ABSTRACT
, childhood OSAS is a clinically entity quite distinct from the adult form, with etiology predominantly featuring lymphoid organ hypertrophy, making adenotonsillectomy the first-line treatment attitude. Guilleminault 7 , however, analyzed files for 400 children with apnea managed by adenotonsillectomy, and reported persistent In children, retromandibulism is managed in orthopedics, using growth activators, which modify the oral and facial environment and thus, via various mechanisms, contribute to correcting class II malocclusion.
sleep disordered breathing in 14.5% of cases, characterized by pharyngeal narrowing and maxillary hypertrophy and/or retromandibulism.
Although adenotonsillectomy is the first-line treatment, in case of endognathia and/or mandibular retrognathia orthopedic correction is mandatory. The present article focuses exclusively on management of retromandibulism. , we use a monoblock activator to which we have associated an extra-oral force (Fig. 1) .
Why associate an extra-oral force (EOF)? A major side-effect of activators is that they induce a clockwise maxillary and dental tilt and mandibular posterior rotation, impairing class II correction and increasing the vertical dimension. Associating EOF limits these side-effects by altering the resultant force pattern with respect to the maxillary and dental centers of resistance 10,2 ( Fig. 2 ). Vertical control is improved and mandibular response is thereby optimized, freeing the oropharynx and thus facilitating breathing.
The effects to be expected with an activator and associated EOF are basically: -dental-alveolar modifications; -restricted maxillary growth; -mandibular growth stimulation; -and horizontal expression of the mandibular growth (Fig. 3) . There are very few reports on the impact of treatment for retromandibulism on the airways. Comparing teleradiographs before and after by the ramus against optimal values: for ratios >79%, good growth response can be expected (Felpeto 6 ). Petrovic, Stutzmann and Lavergne 9 determined mandibular auxologic potential on a decision tree combining biological data (bone renewal rate) and cephalometry (bone base position and rotational type).
growth activator treatment, it seems, quite subjectively, that the airway occupies a wider "area" after treatment (Fig. 4, 5 and 6) . And "objectively"? In 2010, Paluch's thesis 8 studied variations in airway area on lateral radiographs in patients managed by activator versus controls.
"Results showed a highly significant difference (p = 0.007) in norma lateralis airway area growth between subjects treated by activators (+14%) or not (+8%), independently of gender, baseline typology or degree of propulsion applied. "
But, does breathing improve with this norma lateralis airway area growth?
In 2012, Julia Cohen-Levy 4 , in her thesis, reported a randomized clinical study comparing 19 children (mean age, 6.86 years) treated using a mandibular advancement device for 6 MANDIBULAR GROWTH ACTIVATORS AND CHILDHOOD OSAS months and 13 untreated control subjects (mean age, 7.34 years). Patients were assessed using a questionnaire, polysomnography and ENT and orthodontic clinical examination, but without X-ray or cephalometry, in line with US guidelines. At 6 months, AHI was significantly reduced in the treatment group (p = 0.001) and unchanged in controls. In 64.2% of the treatment group, AHI fell by at least 50%, indicating treatment efficacy against OSAS, in parallel to correction of malocclusion.
Obviously, more thorough studies will be needed to confirm, refine or disprove these observations. In children with retrognathia and OSAS, correction of retromandibulism by growth activator is an indispensable complement to adenotonsillectomy.
In children with retrognathia but free of OSAS, correction of retromandibulism by growth activator not only The objective is to free the oropharynx as well as possible, be the intention curative or preventive.
